Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).

MLA

Bahlis, Nizar J., et al. “Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 39, no. 32, Nov. 2021, pp. 3602–12. EBSCOhost, https://doi.org/10.1200/JCO.21.00443.

APA

Bahlis, N. J., Baz, R., Harrison, S. J., Quach, H., Ho, S.-J., Vangsted, A. J., Plesner, T., Moreau, P., Gibbs, S. D., Coppola, S., Yang, X., Al Masud, A., Ross, J. A., Bueno, O., & Kaufman, J. L. (2021). Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 39(32), 3602–3612. https://doi.org/10.1200/JCO.21.00443

Chicago

Bahlis, Nizar J, Rachid Baz, Simon J Harrison, Hang Quach, Shir-Jing Ho, Annette Juul Vangsted, Torben Plesner, et al. 2021. “Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 39 (32): 3602–12. doi:10.1200/JCO.21.00443.